The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Widespread adoption of CAR-T therapy in the UK: fostering specialist networks
In this video, Andrea Kuhnl, MD, King’s College Hospital, London, UK, briefly discusses the potential challenges associated with the widespread adoption of CAR T-cell therapy and other immunotherapies in the UK. Dr Kuhnl highlights the need to consider individual patient eligibility and the complexity of selecting the best product and sequence of immunotherapies, which may require collaborative network structures involving CAR-T centers and referring centers to optimize treatment recommendations. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think access in general has improved in the UK with the addition of more CAR-T delivery centers and I think the challenge for the future will be more to consider CAR-T for really all patients who are eligible and suitable with more products becoming available, more immunotherapy like bispecific antibodies, it will really be a challenge to find the best product and immunotherapy sequence for each individual patient...
So I think access in general has improved in the UK with the addition of more CAR-T delivery centers and I think the challenge for the future will be more to consider CAR-T for really all patients who are eligible and suitable with more products becoming available, more immunotherapy like bispecific antibodies, it will really be a challenge to find the best product and immunotherapy sequence for each individual patient. This might not always be straightforward answers, so really important to consolidate and foster these network structures where we jointly discuss and review patients with the CAR-T center and referring centers’ input to come to the best recommendation for each patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
